Professional edition active

Guidelines for Chelation Therapy

Chelating Agent*

Metal

Dosage

Deferasirox/deferiprone/deferoxamineDeferasirox/deferiprone/deferoxamine

Iron

See Treatment of Iron Poisoning

Dimercaprol, 10% in oilDimercaprol, 10% in oil

Antimony

Arsenic

Bismuth

Copper saltsCopper salts

Gold

Lead

Mercury

Thallium*

3–4 mg/kg via deep IM injection every 4 hours on day 1; 2 mg/kg IM every 4 hours on day 2; 3 mg/kg IM every 6 hours on day 3; then 3 mg/kg IM every 12 hours for 7–10 days until recovery

Edetate calcium disodium (calcium disodium edathamil) diluted to Edetate calcium disodium (calcium disodium edathamil) diluted to 3%

Cobalt

Lead

Zinc

Zinc saltsZinc salts

25–35 mg/kg via deep IM injection or IV slowly (over 1 hour) every 12 hours for 5–7 days, followed by 7 days without the medication; then repeated

PenicillaminePenicillamine

Arsenic

Copper saltsCopper salts

Gold

Lead

5–7.5 mg/kg orally 4 times a day (usual starting dose is 250 mg 4 times a day) to a maximum adult dose of 2 g/day

SuccimerSuccimer

Arsenic (occupational exposure in adults)

Cadmium salts

Lead if children have blood lead levels > 45 mcg/dL (> 2.15 micromol/L)

Lead (occupational exposure in adults)

Mercury (occupational exposure in adults)

10 mg/kg orally every 8 hours for 5 days, then 10 mg/kg orally every 12 hours for 14 days

Triethylenetetramine

CopperCopper

Dosing for Wilson disease only

13 years and older: 750–1250 mg, orally, in divided doses given 2, 3, or 4 times daily; maximum dose: 2000 mg daily

12 and under: 500–750 mg, orally, in divided doses given 2, 3, or 4 times daily; maximum dose: 1500 mg daily

* Thallium salts are chelated with varying success by this medication (see thallium salts in table Symptoms and Treatment of Specific Poisons).

Dosages depend on type and severity of poisoning.

This chelating agent was approved in 2018 for treatment of Wilson disease; it was not approved for use in the treatment of exogenous copper intoxication. This chelating agent was approved in 2018 for treatment of Wilson disease; it was not approved for use in the treatment of exogenous copper intoxication.